A quick look at the OPUS study
Estrogen plays an important role in bone metabolism, especially the mechanisms related to calcium resorption. For post-menopausal women, bone mineral density and content are more rapidly reduced as their bodies naturally produce less estrogen.
Isoflavones, as phytoestrogens, can activate estrogen receptors in the bones, and reduce bone resorption.
SoyLife® has been used in multiple studies examining bone health. These studies range from short-term studies following biochemical markers of bone metabolism, to long-term intervention studies measuring bone mineral density and content.
SoyLife® was used in a long-term US study on the effects of soy supplementation on osteoporosis. Results of the study show positive effects of SoyLife® on bone health parameters. In addition, the long term use of SoyLife® for 2 years was revealed to be safe.
A multicenter, randomized, double-blind, placebo-controlled 24-month trial was conducted to assess the effects of daily supplementation with 80 or 120 mg of SoyLife® supplemented with calcium and vitamin D on bone changes in 403 postmenopausal women. Study subjects were tested annually and changes in whole-body and regional bone mineral density and T scores were assessed. Changes in serum biochemical markers of bone metabolism were also assessed.
Study participants receiving a daily supplement with 120 mg soy isoflavones had a significantly smaller reduction in whole-body bone mineral density than did the placebo group both at 1 y (P < 0.03) and at 2 y (P < 0.05) of treatment.
Daily supplementation with 120 mg SoyLife® reduces whole-body bone loss in healthy postmenopausal women.